The First Thermic Treatment Predicts Following Chemoradiation Response with Concurrent Thermal Therapy for the Treatment of Rectal Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jun 22

PMID 29928438

Authors

Hisanori Shoji

Masahiko Motegi

Kiyotaka Osawa

Takayuki Asao

Hiroyuki Kuwano

Takeo Takahashi

Kyoji Ogoshi

Affiliations

Soon will be listed here.

Abstract

The present study aimed to evaluate whether the neoadjuvant chemoradiation response with concurrent thermal therapy for the treatment of rectal cancer can be predicted following the first thermic treatment. Eighty patients with primary rectal adenocarcinoma (≤12 cm from the anal verge) were included in this study. Fifty-four received surgery and pathological response was evaluated. Intensity-modulated radiotherapy was administered conventionally once daily 5 times/week. Neoadjuvant radiotherapy consisted of 50 Gy delivered to the planning target volume in 25 fractions. Concurrent neoadjuvant chemotherapy was delivered in 5-day courses. Capecitabine was administered orally at 1,700 mg/m/day for 5 days/week. Thermic treatment was performed using the Thermotron-RF 8 and administered once/week for 5 weeks with 50 min irradiation. Patients with a gross tumor volume (GTV) ≤32 cm and a radiofrequency (RF) output difference (RO difference) ≥77 Watt/min exhibited pathological complete response (pCR) and CR rates of 50 and 75%, respectively. Those with a GTV ≥80 cm and a RO difference ≥77 Watt/min exhibited pCR and CR rates of 42.9 and 42.9%, respectively. The changes in the skin temperature during RF treatment in patients with pCR with a RO difference ≥77 Watt/min increased significantly compared with those of other outcomes, and progressive disease. These data suggest a strategy for predicting which patients will respond best following the first thermic treatment. The results identified that the group of patients with a GTV ≤32 cm and a RO difference ≥77 Watt/min (outputable/heatable patients) may respond best.

References

Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C . Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 30(16):1926-33. DOI: 10.1200/JCO.2011.40.1836. View

Zhu J, Gu W, Lian P, Sheng W, Cai G, Shi D . A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma. Radiat Oncol. 2013; 8:130. PMC: 3680166. DOI: 10.1186/1748-717X-8-130. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Roh M, Colangelo L, OConnell M, Yothers G, Deutsch M, Allegra C . Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009; 27(31):5124-30. PMC: 2773471. DOI: 10.1200/JCO.2009.22.0467. View

Peeters K, Marijnen C, Nagtegaal I, Kranenbarg E, Putter H, Wiggers T . The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007; 246(5):693-701. DOI: 10.1097/01.sla.0000257358.56863.ce. View

Schroeder C, Gani C, Lamprecht U, von Weyhern C, Weinmann M, Bamberg M . Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone. Int J Hyperthermia. 2012; 28(8):707-14. DOI: 10.3109/02656736.2012.722263. View

Valentini V, Gambacorta M, Barbaro B, Chiloiro G, Coco C, Das P . International consensus guidelines on Clinical Target Volume delineation in rectal cancer. Radiother Oncol. 2016; 120(2):195-201. DOI: 10.1016/j.radonc.2016.07.017. View

Shoji H, Motegi M, Osawa K, Okonogi N, Okazaki A, Andou Y . Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer. Oncol Rep. 2016; 35(5):2569-75. PMC: 4811390. DOI: 10.3892/or.2016.4659. View

Guo Z, Shu Y, Zhou H, Zhang W, Wang H . Radiogenomics helps to achieve personalized therapy by evaluating patient responses to radiation treatment. Carcinogenesis. 2015; 36(3):307-17. DOI: 10.1093/carcin/bgv007. View

10.

Yerushalmi R, Idelevich E, Dror Y, Stemmer S, Figer A, Sulkes A . Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. J Surg Oncol. 2006; 93(7):529-33. DOI: 10.1002/jso.20503. View

11.

Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C . Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014; 32(15):1554-62. DOI: 10.1200/JCO.2013.54.3769. View

12.

Das P, Lin E, Bhatia S, Skibber J, Rodriguez-Bigas M, Feig B . Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006; 66(5):1378-83. DOI: 10.1016/j.ijrobp.2006.07.1374. View

13.

Elshazly W, Farouk M, Samy M . Preoperative concomitant radiotherapy with oral capecitabine in advanced rectal cancer within 6 cm from anal verge. Int J Colorectal Dis. 2008; 24(4):401-7. DOI: 10.1007/s00384-008-0623-9. View

14.

Krishnan S, Janjan N, Skibber J, Rodriguez-Bigas M, Wolff R, Das P . Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006; 66(3):762-71. DOI: 10.1016/j.ijrobp.2006.05.063. View

15.

Maluta S, Romano M, DallOglio S, Genna M, Oliani C, Pioli F . Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum. Int J Hyperthermia. 2010; 26(2):108-17. DOI: 10.3109/02656730903333958. View

16.

Park I, You Y, Agarwal A, Skibber J, Rodriguez-Bigas M, Eng C . Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012; 30(15):1770-6. PMC: 3383178. DOI: 10.1200/JCO.2011.39.7901. View

17.

Bosset J, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun R . Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014; 15(2):184-90. DOI: 10.1016/S1470-2045(13)70599-0. View

18.

De Paoli A, Chiara S, Luppi G, Friso M, Beretta G, Del Prete S . Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol. 2005; 17(2):246-51. DOI: 10.1093/annonc/mdj041. View

19.

Powathil G, Adamson D, Chaplain M . Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational model. PLoS Comput Biol. 2013; 9(7):e1003120. PMC: 3708873. DOI: 10.1371/journal.pcbi.1003120. View

20.

Holck S, Nielsen H, Pedersen N, Larsson L . Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma. Oncotarget. 2015; 6(33):34321-8. PMC: 4741455. DOI: 10.18632/oncotarget.5761. View